研究者詳細 - 枝村　康平

論文 - 枝村　康平

分割表示 224 件中 201 - 220 件目／全件表示 >>

陰茎原発epithelioid sarcomaに対し陰茎全摘除術後に尿道陰茎再建術行った1例

西村慎吾, 枝村康平, 小林泰之, アバラズア・フェルナンド, 石井和史, 雑賀隆史, 那須保友, 公文裕巳

西日本泌尿器科 71 ( 増刊 ) 132 - 132 2009年10月

Functional analysis of secreted caveolin-1 in mouse models of prostate cancer progression. 国際誌

Masami Watanabe, Guang Yang, Guangwen Cao, Salahaldin A Tahir, Koji Naruishi, Ken-Ichi Tabata, Elmoataz Abdel Fattah, Kartik Rajagopalan, Terry L Timme, Sanghee Park, Shinji Kurosaka, Kohei Edamura, Ryuta Tanimoto, Francesco J Demayo, Alexei A Goltsov, Timothy C Thompson

Molecular cancer research : MCR 7 ( 9 ) 1446 - 55 2009年9月

記述言語：英語掲載種別：研究論文（学術雑誌）

Previously, we reported that caveolin-1 (cav-1) is overexpressed in metastatic prostate cancer and that virulent prostate cancer cells secrete biologically active cav-1. We also showed that cav-1 expression leads to prosurvival activities through maintenance of activated Akt and that cav-1 is taken up by other cav-1-negative tumor cells and/or endothelial cells, leading to stimulation of angiogenic activities through PI-3-K-Akt-eNOS signaling. To analyze the functional consequences of cav-1 overexpression on the development and progression of prostate cancer in vivo, we generated PBcav-1 transgenic mice. Adult male PBcav-1 mice showed significantly increased prostatic wet weight and higher incidence of epithelial hyperplasia compared with nontransgenic littermates. Increased immunostaining for cav-1, proliferative cell nuclear antigen, P-Akt, and reduced nuclear p27(Kip1) staining occurred in PBcav-1 hyperplastic prostatic lesions. PBcav-1 mice showed increased resistance to castration-induced prostatic regression and elevated serum cav-1 levels compared with nontransgenic littermates. Intraprostatic injection of androgen-sensitive, cav-1-secreting RM-9 mouse prostate cancer cells resulted in tumors that were larger in PBcav-1 mice than in nontransgenic littermates (P = 0.04). Tail vein inoculation of RM-9 cells produced significantly more experimental lung metastases in PBcav-1 males than in nontransgenic male littermates (P = 0.001), and in cav-1(+/+) mice than in cav-1(-/-) mice (P = 0.041). Combination treatment with surgical castration and systemic cav-1 antibody dramatically reduced the number of experimental metastases. These experimental data suggest a causal association of secreted cav-1 and prostate cancer growth and progression.

DOI： 10.1158/1541-7786.MCR-09-0071

PubMed

researchmap

進行性尿路上皮癌に対するGCP療法の検討

枝村康平, 雑賀隆史, 谷本竜太, 高尾彰, 小林泰之, 上杉達也, 賀来春紀, 那須保友, 公文裕巳

日本癌治療学会誌 44 ( 2 ) 593 - 593 2009年9月

上部尿路疾患に対する腎盂尿管鏡の有用性に関する検討

高尾彰, 雑賀隆史, 枝村康平, 小林泰之, 小武家誠, 上杉達也, 上原慎也, 賀来春紀, 門田晃一, 那須保友, 公文裕巳

日本癌治療学会誌 44 ( 2 ) 763 - 763 2009年9月

進行性尿路上皮癌に対するGemcitabine(GEM)、Cisplatin(CDDP)、Paclitaxel(PAC)-GCP療法-の検討

枝村康平, 雑賀隆史, 和田耕一郎, 谷本竜太, 高尾彰, 小林泰之, 小武家誠, 上杉達也, 賀来春紀, 那須保友, 公文裕巳

西日本泌尿器科 71 ( 8 ) 435 - 435 2009年8月

Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer. 国際誌

K Tabata, M Watanabe, K Naruishi, K Edamura, T Satoh, G Yang, E Abdel Fattah, J Wang, A Goltsov, D Floryk, S D Soni, D Kadmon, T C Thompson

Prostate cancer and prostatic diseases 12 ( 3 ) 301 - 9 2009年

記述言語：英語掲載種別：研究論文（学術雑誌）

We evaluated the potential use of intraoperative gelatin matrix hemostatic sealant (GMHS; FloSeal; Baxter Healthcare) embedded with macrophages (Mphi) transduced with murine interleukin (IL)-12 recombinant adenoviral vector (G/Mphi/AdmIL-12) for prevention of recurrence of prostate cancer following radical prostatectomy. Application of G/Mphi/AdmIL-12 resulted in significant suppression of tumor growth and spontaneous lung metastases, a statistically significant survival advantage of the G/Mphi/AdmIL-12-treated animals, more efficient trafficking of Mphi to lymph nodes draining from the prostate and generation of systemic natural killer cell activity and tumor-specific cytolytic T lymphocyte responses compared to the controls in a preclinical mouse model of residual prostate cancer. Our data recommend this treatment as a novel adjuvant for prevention of local recurrence of prostate cancer following radical prostatectomy.

DOI： 10.1038/pcan.2008.57

PubMed

researchmap

JUP1-2 腎癌に対するCTガイド下経皮的ラジオ波焼灼療法(JUAアップデートセッションパネルディスカッション1「エンドユロロジー・腹腔鏡領域」,第97回日本泌尿器科学会総会)

小林泰之, 郷原英夫, 枝村康平, 小武家誠, 上杉達也, 雑賀隆史, 那須保友, 金澤右, 公文裕巳

日本泌尿器科学会雑誌 100 ( 2 ) 77 - 77 2009年

PP-286 前立腺癌永久密封小線源治療に合併する排尿障害に対するα1受容体遮断薬の改善効果に関する検討(Neurourology/臨床3,一般演題ポスター,第97回日本泌尿器科学会総会)

上松克利, 佐々木克己, 渡辺豊彦, 上原慎也, 小武家誠, 上杉達也, 枝村康平, 川口正志, 雑賀隆史, 那須保友, 公文裕己

日本泌尿器科学会雑誌 100 ( 2 ) 388 - 388 2009年

難治性尿路上皮癌および精巣腫瘍に対する化学療法難治性精巣腫瘍にたいする3rd line化学療法としてのGemcitabine(GEM)、Cisplatinum(CDDP)、Paclitaxel(PTX)併用療法の経験

雑賀隆史, 小武家誠, 上杉達也, 小林泰之, 谷本竜太, 枝村康平, 賀来春紀, 那須保友, 公文裕巳

西日本泌尿器科 70 ( 増刊 ) 112 - 112 2008年10月

切除不能・再発尿路上皮癌に対するGemcitabine(GEM)、Cisplatin(CDDP)、Paclitaxel(PAC)-GCP療法-の検討

谷本竜太, 枝村康平, 雑賀隆史, 和田耕一郎, 小林泰之, 小武家誠, 大和豊子, 賀来春紀, 那須保友, 公文裕巳

日本癌治療学会誌 43 ( 2 ) 486 - 486 2008年10月

再燃進行前立腺がんの治療の現状と展望再燃前立腺がんに対する遺伝子治療の現況と展望査読

那須保友, 賀来春紀, 渡部昌実, 枝村康平, 谷本竜太, Abaruz Fernando, 黄鵬, 佐々木克己, 雑賀隆史, 公文裕巳

泌尿器外科 21 ( 8 ) 1049 - 1051 2008年8月

記述言語：日本語出版者・発行元：医学図書出版(株)

再燃前立腺がんに対する新たな治療法として遺伝子治療の基礎研究は分子生物学の進歩に伴いその成果を挙げてきた。さらにこれらの基礎研究の成果を臨床に還元するための研究(トランスレーショナルリサーチ)としてわれわれは遺伝子治療臨床研究を実施してきた。われわれが実施してきた自殺遺伝子としてのHSV-tk遺伝子、Interleukin-12遺伝子、腫瘍融解アデノウイルス、新規がん抑制遺伝子REICを用いた遺伝子治療研究の成果を概説することで再燃前立腺がんに対する遺伝子治療の現況とその展望を述べた。(著者抄録)

J-GLOBAL

researchmap

Iodine-125 seed implantation (permanent brachytherapy) for clinically localized prostate cancer.

Shin Ebara, Norihisa Katayama, Ryuta Tanimoto, Kohei Edamura, Hiroyuki Nose, Daisuke Manabe, Tomoko Kobayashi, Yasuyuki Kobayashi, Makoto Kobuke, Mitsuhiro Takemoto, Takashi Saika, Yasutomo Nasu, Susumu Kanazawa, Hiromi Kumon

Acta medica Okayama 62 ( 1 ) 9 - 13 2008年2月

記述言語：英語掲載種別：研究論文（学術雑誌）

From January 2004 to March 2007, 308 patients with clinically localized prostate cancer were treated using iodine-125 (125I) seed implantation (permanent brachytherapy) at Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. We evaluated the treatments efficacy and morbidity in 300 prostate cancer patients who were followed up for more than 1 month after brachytherapy. Based on the National Comprehensive Cancer Network (NCCN) guidelines, patients with a prostate volume of less than 40 ml in transrectal ultrasound imaging were classified as low or intermediate risk. The median patient age was 67 years (range 50 to 79 years), the median prostate-specific antigen (PSA) value before biopsy was 6.95 ng/ml (range 1.13 to 24.7 ng/ml), and the median prostate volume was 24.33 ml (range 9.3 to 41.76 ml). The median follow-up was 18 months (range 1 to 36 months) and the PSA levels decreased in almost all patients after brachytherapy. Although 194 of 300 patients (64.7%) complained of difficulty in urination, pollakisuria/urgency, miction pain, and/or urinary incontinence, all of which might be associated with radiation prostatitis during the first month after brachytherapy, these symptoms gradually improved. 125I seed implantation brachytherapy is safe and effective for localized prostate cancer within short-term follow up.

PubMed

researchmap

Adenovirus-mediated REIC/Dkk-3 gene transfer inhibits tumor growth and metastasis in an orthotopic prostate cancer model. 国際誌

K Edamura, Y Nasu, M Takaishi, T Kobayashi, F Abarzua, M Sakaguchi, Y Kashiwakura, S Ebara, T Saika, M Watanabe, N-H Huh, H Kumon

Cancer gene therapy 14 ( 9 ) 765 - 72 2007年9月

記述言語：英語掲載種別：研究論文（学術雑誌）

We had previously reported that REIC/Dkk-3, a member of the Dickkopf (Dkk) gene family, works as a tumor suppressor. In this study, we evaluated the therapeutic effects of an intratumoral injection with adenoviral vector encoding REIC/Dkk-3 gene (Ad-REIC) using an orthotopic mouse prostate cancer model of RM-9 cells. We also investigated the in vivo anti-metastatic effect and in vitro anti-invasion effect of Ad-REIC gene delivery. We demonstrated that the Ad-REIC treatment inhibited prostate cancer growth and lymph node metastasis, and prolonged mice survival in the model. These therapeutic responses were consistent with the intratumoral apoptosis induction and in vitro suppression of cell invasion/migration with reduced matrix metalloprotease-2 activity. We thus concluded that in situ Ad-REIC/Dkk-3 gene transfer may be a promising therapeutic intervention modality for the treatment of prostate cancer.

PubMed

researchmap

Heat shock proteins play a crucial role in tumor-specific apoptosis by REIC/Dkk-3. 国際誌

Fernando Abarzua, Masakiyo Sakaguchi, Ryuta Tanimoto, Hiroyuki Sonegawa, Dai-Wei Li, Kohei Edamura, Tomoko Kobayashi, Masami Watanabe, Yuji Kashiwakura, Haruki Kaku, Takashi Saika, Keiichiro Nakamura, Yasutomo Nasu, Hiromi Kumon, Nam-Ho Huh

International journal of molecular medicine 20 ( 1 ) 37 - 43 2007年7月

記述言語：英語掲載種別：研究論文（学術雑誌）

We recently showed that overexpression of REIC/Dickkopf-3 (Dkk-3), a tumor suppressor gene, induced apoptosis in a tumor cell-specific manner. The aim of the present study was to determine the mechanisms underlying the selective induction of apoptosis. At first, we found a mouse renal carcinoma cell line, RENCA, to be extremely sensitive to an adenovirus carrying REIC/Dkk-3 (Ad-REIC), and we showed that activation of c-Jun N-terminal kinase (JNK) was a critical step in cell death, i.e. a process similar to that in human prostate and testicular cancer observed in our previous studies. Among the proteins interfering with the activation of JNK, heat shock protein (Hsp)70/72 was reduced in expression in RENCA cells compared with that in NIH3T3 cells. An Hsp70/72 inducer protected RENCA cells from Ad-REIC-induced apoptosis, while an Hsp70/72 inhibitor sensitized NIH3T3 cells for apoptosis induction. These results indicate that functionally active Hsp70/72 is a key factor in tumor cell-specific induction of apoptotic cell death and that analyses of the expression levels of Hsp70/72 may be essential in determining the significance of Ad-REIC-based gene therapy against human cancer.

PubMed

researchmap

Adenovirus-mediated REIC/Dkk-3 gene transfer inhibits tumor growth and metastasis in an orthotopic prostate cancer model

K Edamura , Y Nasu , M Takaishi , T Kobayashi , F Abarzua , M Sakaguchi , Y Kashiwakura , S Ebara , T Saika , M Watanabe , N-H Huh , H Kumon

Cancer Gene Therapy 14 765 - 772 2007年

S11-6 密封小線源療法を施行された前立腺癌患者のQOLに関する研究 : 恥骨後式根治的前立腺摘除術とのProspectiveな比較において(シンポジウム11「限局性前立腺癌の治療成績とQOL」,第94回日本泌尿器科学会総会)

雑賀隆史, 江原伸, 真鍋大輔, 能勢宏幸, 枝村康平, 谷本竜太, 小林知子, 津島知靖, 那須保友, 中西代志子, 公文裕巳

日本泌尿器科学会雑誌 97 ( 2 ) 165 - 165 2006年

MP-453 1251シード線源による前立腺癌永久挿入密封小線源治療(一般演題ポスター,第94回日本泌尿器科学会総会)

江原伸, 真鍋大輔, 枝村康平, 谷本竜太, 小林知子, 雑賀隆史, 那須保友, 公文裕巳

日本泌尿器科学会雑誌 97 ( 2 ) 480 - 480 2006年

OP-119 進行性尿路上皮癌に対するGemcitabine (GEM)、Cisplatin (CDDP)、Paclitaxel (PAC) -GCP療法-の検討(一般演題口演,第94回日本泌尿器科学会総会)

谷本竜太, 眞鍋大輔, 和田耕一郎, 枝村康平, 小林知子, 賀来春紀, 江原伸, 大和豊子, 雑賀隆史, 那須保友, 公文裕巳

日本泌尿器科学会雑誌 97 ( 2 ) 310 - 310 2006年

Long-term clinical outcomes of 420 consecutive prostate cancer patients in a single institute.

Kohei Edamura, Takashi Saika, Takashi Senoh, Fumihito Koizumi, Daisuke Manabe, Shin Ebara, Haruki Kaku, Teruhiko Yokoyama, Fernando Abarzua, Atsushi Nagai, Yasutomo Nasu, Tomoyasu Tsushima, Hiromi Kumon

Acta medica Okayama 59 ( 5 ) 195 - 9 2005年10月

記述言語：英語掲載種別：研究論文（学術雑誌）

This study was undertaken to reveal the trends of prostate cancer and the outcome of treatment modalities for each disease stage in patients in a single institute over a 10-year period. From January 1994 through December 2003, 420 consecutive patients with previously untreated and histologically confirmed prostate cancer were analyzed for annual distributions of disease stages and treatment modalities and for long-term clinical progression-free survival, prostate cancer-specific survival, and prostate-specific antigen (PSA) failure-free survival rates for each stage and treatment modality. Annual trends showed that the number of patients, especially those with clinically localized cancer, increased dramatically. The 5-year disease-specific survival rates for patients with clinically localized disease were 100 percent for all treatment modalities, including hormonal therapy alone. Patients with PSA levels less than 10 ng/ml showed an 81 percent 5-year PSA failure-free survival rate with radical prostatectomy. Stage C patients treated by surgery or radiation-based therapy with concomitant hormonal therapy obtained 93 percent and 100 percent cause-specific survival rates, respectively, and those treated by hormonal therapy alone showed a 79 percent rate. The number of patients with localized prostate cancer was increasing in this decade. While long-term hormonal therapy alone was highly efficient in controlling localized prostate cancer, radical therapies in conjunction with neo-adjuvant hormonal therapy produced better survival rates in cases of locally advanced disease.

PubMed

researchmap

^<125>Iシード線源による前立腺癌永久刺入密封小線源治療(第93回日本泌尿器科学会総会)

江原伸, 真鍋大輔, 能勢宏幸, 枝村康平, 雑賀隆史, 那須保友, 公文裕巳

日本泌尿器科学会雑誌 96 ( 2 ) 426 - 426 2005年

　前のページ - 次のページ　

<枝村 康平>

論文 - 枝村 康平

<枝村　康平>

論文 - 枝村　康平